Processa Pharmaceuticals (PCSA) 10-Q2023 Q2 Quarterly report

Filed: 10 Aug 23, 4:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: Absent, adhere, affirmative, analyst, appointed, assumption, bid, carefully, classification, cohort, compliance, coverage, covered, declaring, defense, delist, Department, domestic, doubt, eligible, employment, environment, exhaust, expertise, face, favorable, Floyd, foreign, fulltime, George, instruction, letter, listed, listing, Michael, minimum, National, navigating, Ng, notifying, penny, President, rapid, recoverability, regain, relinquish, resigned, Rule, satisfy, scope, seasoned, statute, stringent, Subsequent, transition, Uncertainty, valuable, written

Removed: accrued, agreed, liability, month, past, team, tolerability, twelve, warrant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PCSA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Written Statement of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. §1350

Solely for the purposes of complying with 18 U.S.C. §1350, I, the undersigned President, Research and Development (Acting Principal Executive Officer) of Processa Pharmaceuticals, Inc. (the “Company”), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the quarter ended June 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

	By:	/s/ Dr. David Young
		Dr. David Young
		President, Research and Development
		(Acting Principal Executive Officer)

	Date:	August 10, 2023

Solely for the purposes of complying with 18 U.S.C. §1350, I, the undersigned Chief Financial Officer of Processa Pharmaceuticals, Inc. (the “Company”), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the quarter ended June 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ James Stanker
		James Stanker
		Chief Financial Officer (Principal Financial and Accounting Officer)

	Date:	August 10, 2023

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.